On March 12, 2026, Eli Lilly and Company issued an open letter to the public, warning of potential safety risks associated with compounded medications that mix tirzepatide with vitamin B12.
Lilly stated that its testing revealed a chemical reaction between tirzepatide and B12 in compounded formulations, producing significant levels of unknown impurities. The short term and long term effects of these impurities on the human body remain completely unknown. This warning has once again drawn public attention to the gray area of compounded drug formulations.

Unknown Impurities Detected
Safety Profile Completely Unknown
In its open letter, Eli Lilly disclosed that it had tested commercially available compounded products combining tirzepatide with B12 (including methylcobalamin, hydroxocobalamin, or cyanocobalamin) and found them to contain substantial levels of unknown impurities. These impurities are products of a chemical reaction between tirzepatide and B12. Lilly emphasized that no research data exist regarding the pharmacological properties of these impurities—including their interactions with GLP 1 and GIP receptors, potential toxicity, immunogenicity, and their absorption, distribution, metabolism, and excretion in humans.
The company further noted that no clinical studies have ever been conducted on the combination of tirzepatide and B12. Moreover, facilities producing such compounded products are not required to monitor or report adverse events. This means patients using these products are exposed to completely uncharacterized risks. Lilly has notified the U.S. Food and Drug Administration (FDA) of its findings and recommends that patients currently using such products immediately consult their healthcare providers to discuss alternative treatment options.

Evading Regulation in the Name of “Personalization”
Yet Carrying Multiple Safety Hazards
The open letter also exposed a common practice in the compounding industry: some facilities add untested ingredients such as vitamin B12, glycine, pyridoxine, niacinamide, and carnitine to tirzepatide, claiming to offer “personalized” medicines, while actually attempting to evade FDA regulations governing large scale compounding. Eli Lilly clearly stated that these additives provide no proven clinical benefit to patients taking tirzepatide, yet introduce unknown risks.
In addition to the newly discovered chemically formed impurities, Lilly’s previous testing has repeatedly identified issues in compounded tirzepatide products, including bacterial contamination, high endotoxin levels, and other impurities not present in FDA approved drugs. Combined, these safety concerns make compounded products far riskier than previously understood. Despite clear directives from the FDA and federal courts to halt large scale compounding of tirzepatide, some facilities continue to operate in violation of regulations.

Implications for Drug Development
This incident carries multiple implications for the drug development industry.
First, it highlights the boundaries of post marketing responsibility for innovative pharmaceutical companies. When an innovator drug is in short supply or carries a high price, the compounding industry often quickly fills the market gap, yet innovator companies typically lack authority over the quality control of these compounded products. Lilly’s proactive testing and public warning demonstrate strong commitment to patient safety and set a benchmark for the industry.
Second, the incident serves as a renewed reminder to the public and regulators that compounded medications are fundamentally different from innovator drugs approved through rigorous clinical trials. The FDA has repeatedly emphasized that compounded drugs carry “higher risks” because their safety, efficacy, and quality have not undergone FDA review. The chemically generated impurities discovered in this case are a concrete manifestation of such risks. For patients, considering compounded medications requires full awareness of their essential differences from approved drugs, and informed decisions should be made under the guidance of a physician.
Finally, this incident also provides a warning for the “follow on development” of the pharmaceutical industry. As a complex peptide molecule, tirzepatide can undergo chemical reactions and form unknown impurities even when mixed with seemingly safe and common additives like vitamin B12. This alerts the industry that any formulation changes, dosage improvements, or combination uses involving biologic and large molecule drugs must undergo rigorous scientific research and clinical trials. Casual, untested mixing can create hidden safety hazards.

Conclusion
Eli Lilly’s public warning is not only a risk alert for compounded tirzepatide products but also a profound reminder to the entire pharmaceutical industry and the public: there are no shortcuts between drug innovation and safety. While pursuing convenience and accessibility, adherence to science based, cautious principles is essential. For patients, thoroughly discussing potential risks with a healthcare provider before considering any unapproved “alternative” remains the first line of defense in protecting personal health.